Skip to main content

Pregnancy

Are We Overcautious With TNF Inhibitors in Pregnancy? What may seem like a prudent approach to treatment of IBD in pregnant women actually represents an overabundance of caution, suggested researchers who found no increased risk from TNF inhibitors.https://t.co/gYqJDBHTBQ https://t.co/aBXl49wJzM
Lasker,award,science,biomedical

2022 Lasker Award Winners

EurekAlert!
Sep 29, 2022

The Lasker Foundation has announced the winners of its 2022 Lasker Awards, widely regarded as America’s top biomedical research prize since its creation more than 75 years ago. Here's a look at the award winners and their important contributions to biomedical research.

Read Article
pregnancy,doctor,consult

Are We Overcautious With TNF Inhibitors in Pregnancy?

MedPage Today
Sep 27, 2022

What may seem like a prudent approach to treatment of inflammatory bowel disease (IBD) in pregnant women actually represents an overabundance of caution, suggested researchers who found no increased risk from tumor necrosis factor (TNF) inhibitors.

Read Article
homunculus.JPG

Disease Activity Drives Adverse Pregnancy Outcomes in RA

Sep 13, 2022

Two large RA registries have shown that pregnancy outcomes in rheumatoid arthritis (RA) patients is more related to RA disease activity rather than treatments use to control RA. 



Analysis of the Swedish Rheumatology Quality Register abd the Danish clinical quality register (DANBIO)

Read Article
73 #RA pregnancies w/ live births. 88% were in remission/low disease before conception. RA flares occurred in 37% (in 1st &2nd trim). Preterm assoc w/ Flares; flares more likely if bDMARD D/C @ +Preg test (55% w/ flare vs. 30% w/o flare, p 0.03, OR 2.9) https://t.co/hVtUuX3lfr https://t.co/bFbyQZbcim
Favorable Pregnancy Outcomes in Spondyloarthritis Pregnancy often occurs in women with axial spondyloarthritis (axSpA), and a recent cohort study suggests outcomes are generally better than what had been reported in the literature. https://t.co/piAjx1Ugsu https://t.co/N6SGYOM6F1
woman-1284353_640.jpg

Favorable Pregnancy Outcomes in Spondyloarthritis

Aug 16, 2022

Pregnancy often occurs in women with axial spondyloarthritis (axSpA), and a recent cohort study suggests outcomes are generally better than what had been reported in the literature.



Data was collected from axSpA patients from 4 registries who were pregnant. This included a total of

Read Article
US national study of shows pregnancy in inflammatory bowel disease pts has higher risks for: - gestational diabetes (AOR) - HTN complications (1.35) - Pre-term births (1.41) - Fetal growth restriction (1.27) - Fetal death (3.21)https://t.co/3XTrrrNmoe https://t.co/udl7dXT5IF
Biomarker,genes

MRP8/14 as a Biomarker in Systemic Juvenile Idiopathic Arthritis

Jul 13, 2022

A large cohort study of children with febrile disorders has demonstrated the diagnostic utility of Myeloid-related protein 8/14 (MRP8/14) in diagnosing systemic JIA patients (SJIA) in clinical practice.



A cohort of 1110 febrile pediatric patients were divided into two cohorts: (cohort

Read Article
Babies! Safety and Outcomes Data on Pregnancies #EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye...https://t.co/piA1zhGyAA https://t.co/Kb68AGZgA1
Axial Spondyloarthritis

ICYMI: Update on Axial SpA at EULAR 2022

Jul 05, 2022

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Read Article
JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok.https://t.co/PoIheshd2n https://t.co/gjTN2Uz4IP https://t.co/OAfLRvSFBs
RheumNow Podcast square

Two Week Twitter (6.17.2022)

Jun 17, 2022

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.




  1. Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast

Read Article
hands pregnant

Improved Pregnancy Outcomes in SLE (2010–2020)

Jun 14, 2022

A retrospective cohort study has shown that outcomes in pregnant systemic lupus erythematosus (SLE) patients has significantly improved in the last decade, but there still is a high risk of adverse pregnancy outcomes (APO).



A retrospective Danish SLE cohort was used to identify

Read Article
Watch this 4 minute video on Belimumab use in pregnancy featuring Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/8uRUIVURHF https://t.co/lbYwHFFJit
Axial Spondyloarthritis

Update on Axial SpA at EULAR 2022

Jun 04, 2022

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Read Article
Babies! Safety and Outcomes Data on Pregnancies #EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye...https://t.co/ulQIo2gdlO https://t.co/dpoMd5Wbah
Pregnancy data in SpA from 122 pts 40% flared during pregnancy, more frequent 2nd trimester, pts w/ axial dz 7 pts required start of TNFi during 2nd or 3rd trimester 40% post-partum @RheumNow #EULAR2022 ABST#POST0151 https://t.co/cdFRhRuCVH
SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimester in those with axial involvement OR post-partum. Seven flares led to TNFi initiation in 2nd or 3rd trimesters and were without correlation in post-partum flares. @RheumNow https://t.co/0ZWjYMwmzn
WATCH: New 2022 ASAS/EULAR Recommendations on the Management of AxSpA Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force. #EULAR2022 https://t.co/AiCNQPm6KB https://t.co/kn4rmcbZrH
woman-1284353_640.jpg

Babies! Safety and Outcomes Data on Pregnancies

Jun 02, 2022

EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye because they can potentially impact medical practice.

Read Article
Women with spondyloarthritis at increased risk of gestational diabetes, elective and emergency C-sections, and spontaneous pre-term birth. Infants were not more likely to be born SGA. @RheumNow #EULAR2022 ABST#OP0126 https://t.co/BTXQqruvPs
Study of 2.9k offspring exposed to adalimumab, infliximab, golimumab during pregnancy, as compared to etanercept and certolizumab showed an adjusted hazard ratio for serious infections of 1.20 (CI 0.54, 2.64). @RheumNow #EULAR2022 ABST#OP0130
Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis). @RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW
#POS0721 #EULAR2022 Are Aspirin + LMWH enough to prevent Adverse Pregnancy Outcomes (preterm, pregnancy loss, eclampsia) in High Risk Triple Antiphospholipid abs+ve + Low C3/C4? An Italian study of 128 patients said NO. Add Hydroxychloroquine @RheumNow https://t.co/927sZoHZEj
×